A Multi-center, Single-arm Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Male and Female Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU)
Latest Information Update: 24 Nov 2025
At a glance
- Drugs Dupilumab (Primary)
- Indications Chronic urticaria
- Focus Pharmacokinetics; Registrational
- Acronyms CINDU CUPIDKids; LIBERTY-CSU; LIBERTY-CSU/CINDU CUPIDKids
- Sponsors Sanofi
Most Recent Events
- 26 Feb 2025 Status changed from active, no longer recruiting to completed.
- 11 Dec 2024 Planned End Date changed from 7 Jul 2025 to 3 Feb 2025.
- 11 Dec 2024 Status changed from recruiting to active, no longer recruiting.